Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$14.08
-0.7%
$13.28
$10.45
$21.69
$4.98B0.62795,464 shs291,452 shs
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$29.24
-2.4%
$32.78
$27.07
$40.28
$1.19B1.31294,906 shs368,898 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$90.99
-0.9%
$96.93
$77.10
$163.71
$5.22B0.78961,610 shs665,653 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$77.36
-4.7%
$83.06
$41.50
$90.32
$4.11B-2.561.08 million shs2.09 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+3.08%+0.35%+3.70%+20.39%-8.52%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
+0.77%+3.86%-10.67%-15.18%-11.75%
Glaukos Corporation stock logo
GKOS
Glaukos
+2.78%+3.71%-12.12%+0.10%-24.45%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-2.66%-0.06%-1.96%+8.09%+63.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.8407 of 5 stars
3.12.00.00.01.31.72.5
Cadre Holdings, Inc. stock logo
CDRE
Cadre
1.5582 of 5 stars
1.01.02.50.01.13.31.9
Glaukos Corporation stock logo
GKOS
Glaukos
4.3186 of 5 stars
3.44.00.04.42.31.70.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.6253 of 5 stars
4.51.00.04.63.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.20
Hold$15.5610.50% Upside
Cadre Holdings, Inc. stock logo
CDRE
Cadre
2.00
Hold$31.507.71% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.85
Moderate Buy$127.4240.03% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.09
Buy$113.3046.46% Upside

Current Analyst Ratings Breakdown

Latest CDRE, GKOS, BLCO, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$38.00 ➝ $26.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $110.00
8/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $13.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$130.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $15.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $92.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$125.00 ➝ $134.00
(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.89B1.02$1.92 per share7.35$18.39 per share0.77
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$572.61M2.08$1.39 per share20.98$8.18 per share3.58
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M13.61N/AN/A$13.34 per share6.82
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$4.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$0.78N/A14.661.40-5.58%2.33%1.12%10/29/2025 (Estimated)
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$36.13M$0.9431.1121.501.106.65%12.08%5.60%N/A
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.14N/AN/AN/AN/A-73.74%-56.67%N/A

Latest CDRE, GKOS, BLCO, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
8/5/2025Q2 2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$0.25$0.30+$0.05$0.30$153.23 million$157.11 million
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.07+$0.01-$0.18$1.25 billion$1.28 billion
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$0.381.30%N/A40.43%2 Years
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A

Latest CDRE, GKOS, BLCO, and SLNO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
quarterly$0.09501.16%8/1/20258/1/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76
1.55
0.98
Cadre Holdings, Inc. stock logo
CDRE
Cadre
0.90
3.59
2.56
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
5.51
4.69
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
15.13
15.01

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
43.95%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
31.50%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.99 million351.30 millionOptionable
Cadre Holdings, Inc. stock logo
CDRE
Cadre
2,28440.66 million27.86 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.35 million54.02 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million49.74 millionOptionable

Recent News About These Companies

SLNO FY2025 EPS Estimate Raised by Cantor Fitzgerald
Soleno Therapeutics's Earnings: A Preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$14.08 -0.09 (-0.66%)
Closing price 03:59 PM Eastern
Extended Trading
$14.09 +0.01 (+0.09%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Cadre stock logo

Cadre NYSE:CDRE

$29.24 -0.71 (-2.36%)
Closing price 03:59 PM Eastern
Extended Trading
$29.21 -0.03 (-0.12%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cadre Holdings, Inc. manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, the Department of Energy, Los Alamos National Laboratories, Waste Isolation Plant, and various foreign government agencies. Cadre Holdings, Inc. was founded in 1964 and is headquartered in Jacksonville, Florida.

Glaukos stock logo

Glaukos NYSE:GKOS

$90.99 -0.80 (-0.87%)
Closing price 03:59 PM Eastern
Extended Trading
$91.02 +0.02 (+0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$77.36 -3.78 (-4.66%)
Closing price 04:00 PM Eastern
Extended Trading
$77.38 +0.02 (+0.02%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.